Press Releases

Press Releases

Samsung Biologics and UCB Sign Third Drug Manufacturing Deal

Samsung Biologics and UCB Sign Third Drug Manufacturing Deal


Incheon, S. Korea, Wednesday July 31, 2019 ? Samsung Biologics (SBL) and UCB have agreed to an additional drug substance manufacturing deal under which SBL will also produce UCB’s anti-tau candidate to treat progressive supranuclear palsy, pending regulatory approvals. UCB’s anti-tau candidate is currently in Phase I clinical studies.

 

UCB is a biopharmaceutical company, headquartered in Belgium, with over 90 years of innovation focusing on neurology and immunology, with an annual revenue of 4.6 billion EUR in 2018. UCB S.A. is listed on Euronext Brussels.

 

“Our aim at UCB is to help people suffering from severe chronic diseases in areas of high unmet needs, and we need to work with organizations with proven track records to secure world class manufacturing capabilities to bring our future drugs to patients,” said Scott Russell, Head of Partnerships & Alliances at UCB. “Samsung Biologics has proven to be a true partner and we are delighted to be working with them on a third consecutive project to complement our internal resources”.

 

“We are extremely proud to further solidify our partnership with UCB, a company with a rich history and vision to innovate healthcare and patient value. This new agreement will also provide us the opportunity to showcase SBL’s newest facility, Plant 3, and demonstrate our proven track record of operational and regulatory success to enable UCB’s treatment of patients with this debilitating disease,” said Dr. Tae Han Kim, President and CEO of Samsung Biologics.

 

This will be the third product from UCB to be supplied by Samsung Biologics under a master services agreement between the parties announced in July 2018. SBL and UCB previously signed two sub-agreements to manufacture UCB’s products currently in clinical development, for addressing the needs of patients effected by myasthenia gravis, psoriasis and psoriatic arthritis.

 

Samsung Biologics building image
 

Samsung Biologics and UCB Sign Third Drug Manufacturing Deal


Incheon, S. Korea, Wednesday July 31, 2019 – Samsung Biologics (SBL) and UCB have agreed to an additional drug substance manufacturing deal under which SBL will also produce UCB’s anti-tau candidate to treat progressive supranuclear palsy, pending regulatory approvals. UCB’s anti-tau candidate is currently in Phase I clinical studies.

 

UCB is a biopharmaceutical company, headquartered in Belgium, with over 90 years of innovation focusing on neurology and immunology, with an annual revenue of 4.6 billion EUR in 2018. UCB S.A. is listed on Euronext Brussels.

 

“Our aim at UCB is to help people suffering from severe chronic diseases in areas of high unmet needs, and we need to work with organizations with proven track records to secure world class manufacturing capabilities to bring our future drugs to patients,” said Scott Russell, Head of Partnerships & Alliances at UCB. “Samsung Biologics has proven to be a true partner and we are delighted to be working with them on a third consecutive project to complement our internal resources”.

 

“We are extremely proud to further solidify our partnership with UCB, a company with a rich history and vision to innovate healthcare and patient value. This new agreement will also provide us the opportunity to showcase SBL’s newest facility, Plant 3, and demonstrate our proven track record of operational and regulatory success to enable UCB’s treatment of patients with this debilitating disease,” said Dr. Tae Han Kim, President and CEO of Samsung Biologics.

 

This will be the third product from UCB to be supplied by Samsung Biologics under a master services agreement between the parties announced in July 2018. SBL and UCB previously signed two sub-agreements to manufacture UCB’s products currently in clinical development, for addressing the needs of patients effected by myasthenia gravis, psoriasis and psoriatic arthritis.

 

Samsung Biologics building image
 

 

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION